05:11:14 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2024-08-20 Kvartalsrapport 2024-Q2
2024-04-11 Årsstämma 2024
2024-04-04 Bokslutskommuniké 2023
2023-12-06 Split ORPHA 1000:1
2023-11-02 Extra Bolagsstämma 2023
2023-09-12 Kvartalsrapport 2023-Q2
2023-05-22 Ordinarie utdelning ORPHA 0.00 DKK
2023-05-17 Årsstämma 2023
2023-04-25 Bokslutskommuniké 2022
2022-09-26 Kvartalsrapport 2022-Q2
2022-06-29 Årsstämma 2022
2022-06-28 Ordinarie utdelning ORPHA 0.00 DKK
2022-06-07 Bokslutskommuniké 2021
2022-02-15 Extra Bolagsstämma 2022
2021-08-31 Kvartalsrapport 2021-Q2
2021-03-26 Ordinarie utdelning ORPHA 0.00 DKK
2021-03-25 Årsstämma 2021
2021-03-02 Bokslutskommuniké 2020
2020-09-21 Extra Bolagsstämma 2020
2020-08-28 Kvartalsrapport 2020-Q2
2020-03-27 Ordinarie utdelning ORPHA 0.00 DKK
2020-03-26 Årsstämma 2020
2020-02-28 Bokslutskommuniké 2019
2020-01-25 Extra Bolagsstämma 2019
2019-08-28 Kvartalsrapport 2019-Q2
2019-03-28 Ordinarie utdelning ORPHA 0.00 DKK
2019-03-27 Årsstämma 2019
2019-03-01 Bokslutskommuniké 2018
2018-08-28 Kvartalsrapport 2018-Q2
2018-04-13 Ordinarie utdelning ORPHA 0.00 DKK
2018-04-12 Årsstämma 2018
2018-03-15 Bokslutskommuniké 2017

Beskrivning

LandDanmark
ListaSmall Cap Copenhagen
SektorHälsovård
IndustriBioteknik
Orphazyme är verksamt inom biokemi. Bolaget är specialiserat mot forskning och utveckling av ovanliga sjukdomar där det finns en brist i funktionen hos värmekokproteiner. Tekniken baseras på arimoklomol, som stimulerar produktionen av värmekokproteiner i celler som upplever en ökad grad av stress och toxicitet. Sjukdomar som ämnar behandlas med bolagets produkter innefattar Gauchers sjukdom och amyotrofisk lateral skleros (ALS). Bolaget har sitt huvudkontor i Köpenhamn.
2023-05-17 15:29:42

Company announcement                                                                                        
Orphazyme A/S
No. 8/2023 
Ole Maaløes Vej 3
DK-2200 Copenhagen N                                                                                                                                                 

www.orphazyme.com
Company Registration No. 32266355

Copenhagen, Denmark, May 17, 2023 – Orphazyme A/S (ORPHA.CO) (the “Company”), today held its Annual General Meeting, at which the Annual General Meeting:

Financial year 2022

  • Took note of the Board of Directors’ report on the Company’s activities in the past financial year;
  • Adopted the Company’s annual report for 2022
  • Adopted that the profit related to the financial year 2022 is carried forward
  • Approved the remuneration report for 2022 (advisory vote)
  • Approved the remuneration of the Board of Directors for 2023

Discharge of liability

  • Granted discharge of liability to the Board of Directors and the Executive Management in relation to the annual report for 2022

Composition of the Board of Directors

  • Bo Jesper Hansen, John Sommer Schmidt and Anders Fink Vadsholt withdrew their candidacies as members of the Board of Directors
  • Michael Hove, Jakob Bendtsen and Jakob Have were elected as new members of the Board of Directors
  • Re-elected EY Godkendt Revisionspartnerselskab as the Company’s auditor in accordance with the recommendation from the Audit Committee
  • After the Company’s Annual General Meeting was held, the Board of Directors constituted itself by appointing Michael Hove as Chairman

An overview of the qualifications and competencies of the new members of the Board of Directors is attached to this announcement.

Proposals by the Board of Directors

  • Adopted to renew the current authorization to the Board of Directors to acquire treasury shares
  • The proposal to adopt a revised remuneration policy was withdrawn

For additional information, please contact

Orphazyme A/S

Michael Hove, Chairman of the board +45 28 12 66 09